A carregar...
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibito...
Na minha lista:
| Publicado no: | J Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ivyspring International Publisher
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5332892/ https://ncbi.nlm.nih.gov/pubmed/28261342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.17144 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|